Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2008

Sosei Out-Licenses Malaria IP to Treague

  • Sosei Group has out-licensed its IP relating to the RS(+) isomer of mefloquine to Treague, for the treatment and prophylaxis of malaria.

    Mefloquine is a antimalarial drug that is approved in its racemic form for both treatment (in combination with artesunate) and prophylaxis (as monotherapy) of malaria. Though its efficacy and long half-life make racemic mefloquine a particularly attractive antimalarial drug, its clinical utility has been compromised by CNS side effects, according to the companies. They believe, based on the stereoselective nature of mefloquine's receptor binding, that RS(+) mefloquine has the potential for substantially reduced CNS side effect liability.

    Treague is collaborating with Medicines for Malaria Venture, a Geneva-based not-for-profit organization dedicated to reducing the burden of malaria, to develop RS(+) mefloquine for the treatment of malaria in malaria endemic countries.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »